3 days popular7 days popular1 month popular3 months popular

Polytherics And Viventia Sponsor ADC Summit, London 2013

are proud to announce that , a and , a Canadian biopharmaceutical company, will be sponsoring this years 2nd annual ADC Summit taking place on 20 – 21 May, London.

Polytherics partners include Spirogen, who have recently announced research collaboration with . The new group effort will evaluate a novel anti-cancer drug conjugate combining Spirogen’s cytotoxic drugs, pyrrolobenzodiazepines (PBD), and associated linker technology, with Nanobodies generated using ’s technology platform. Following on from this both Spirogen and Polytherics will have a presence at the 2nd annual event.

ADC Summit will present attendees with an in-depth view into novel innovations, developments and utilities of antibody-drug conjugates that will see world-renowned expert speakers from , UCB, Bayer, MedImmune, Spirogen and Genentec.

The conference will provide delegates with a unique insight into latest technological and scientific developments and will be the perfect platform for debate and problem-solving discussion.

Attendees will be able to:

  • Listen to Genentech speak on Novel Linker drugs for ADCs
  • See firsthand exactly where the pitfalls and advantages are of developing an anti-body drug conjugate.
  • Learn from expert speakers in the lead of their field from big pharma and biotech companies including Genetech, Immunogen, Spirogen and Bayer
  • Hear from recent advances in conjugate chemistry, target selection, novel payload deliveries, future ADC pipelines and regulatory issues.
  • Network at the UK’s only dedicated event on ADC alongside Agensys, Celgene , Novartis, Sanofi plus many more…

For further information on the conference click here. Alternatively contact Fateja Begum on tel: +44 (0) 20 7827 6184 or email: [email protected]


Source: SMi Group